InVivo Therapeutics (OTC:NVIV) named Mark Perrin as its new CEO, handing him the keys to the corner office effective January 6.
Interim chief Michael Astrue will assist Perrin with the transition, the company said. Astrue took on the position after the resignation of co-founder Frank Reynolds in August, who stepped down over health issues.
Perrin’s background includes stints in leadership roles at ConjuChem Biotechnologies, Orphan Medical, and COR Therapeutics, according to a press release. His fundraising and portfolio building skills should be particularly helpful, InVivo leaders said.
“Mark is an excellent fit for InVivo," chairman John McCarthy said in prepared remarks. "His extensive commercial background will be invaluable to portfolio decisions for our novel hydrogel technology and our new emphasis on partnering as a primary way to finance new programs. He also has solid experience raising money, which will be important to us as we continue to focus our critical resources on high-value opportunities that maximize long-term value for our shareholders."
That’s one seat filled for InVivo, which has been shuffling its top brass lately. InVivo has been going through a CFO swap, recently naming its 3rd since August. Steven McAllister is expected to replace interim CFO Gregory Perry, who left to join an unnamed biotechnology company at the end of last year.